en · de · es
aod-9604-notes.peptides4962.com › Wiki › Identity And Research Background — Background and Details

Identity And Research Background — Background and Details

By Editorial Desk · published 2026-03-26 · last reviewed 2026-04-24 · Wiki

If you have been reading about metabolic research and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2026-04-24. Numbers and descriptions here follow the published literature rather than marketing material.

Identity And Research Background

AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.

AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.

AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.

Research and Regulatory Context

Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.

Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.

AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.

Aod-9604 at a glance

PropertyValueNotes
Molecular classSynthetic peptideFragment analog of human growth hormone
Sequence basishGH 176–191 regionModified C-terminal fragment
Common synonymsAOD-9604; AOD9604; hGH fragmentResearch and trade names vary
Regulatory statusNot approved as a drugProhibited in competitive sport
Research codeAOD9604Used in scientific and patent literature

Identity and Research Origin

AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.

Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.

Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.

Related pages on this site

Background And Research Context

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.

The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.

In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.

Background from the literature

glycol Any of a class of aliphatic dihydric alcohols in which the two hydroxy groups are bonded to two different carbon atoms, which are usually but not necessarily adjacent to each other; e.g. ethylene glycol (HOCH2CH2OH).

=== March === 6 March Astronomers report the discovery of GJ 887 d, a super-Earth exoplanet orbiting the nearby red dwarf star GJ 887. Detected using radial velocity measurements, the planet lies within the star's habitable zone. At just 10.7 light-years, this becomes the second-nearest known exoplanet in the habitable zone after Proxima Centauri b. The UK's first long‑distance robotic-assisted surgery is reported to have been performed on a patient located 1,500 miles (2,400km) away in Gibraltar. 9 March – A study published in Geophysical Research Letters reports with statistical confidence that global warming has accelerated since around 2015, with the rate of increase rising from 0.2 °C to about 0.35 °C per decade after accounting for natural variability. The findings suggest the 1.5 °C threshold could be reached before 2030 if current trends continue. 10 March – A study by Vattenfall and Spoor using AI-assisted video monitoring of 2,007 bird flight paths near an offshore turbine at Aberdeen Bay over 19 months reports no confirmed collisions, with observed avoidance behaviour suggesting lower-than-expected impacts of wind turbines on seabirds. 11 March Two separate studies, published in Environmental Research Letters and Nature Communications, show how net negative emissions will need to be sustained for centuries in order to stabilise global climate change. Astronomers report evidence of a likely collision between two planets orbiting the star Gaia20ehk, about 11,000 light years away in the constellation Puppis.

== Volunteers == CLSI relies on more than 2,000 volunteers. Volunteers and mentors also collaborate with CLSI's Global Health Partnerships to help establish laboratory quality management systems in resource-limited countries.

Abdominal pain Anxiety Panic attacks Depression Piloerection (goose bumps) Inability to enjoy daily activities Muscle and joint pain Nausea Vomiting Runny nose and excessive secretion of tears Sweating In the clinical setting, excessive secretion of tears, yawning, and dilation of pupils are helpful presentations in diagnosing opioid withdrawal. Hydromorphone is a rapid-acting painkiller; however, some formulations may last up to several hours. Patients who stop taking this drug abruptly may experience withdrawal symptoms, which may start within hours of taking the last dose of hydromorphone, and last up to several weeks. Withdrawal symptoms in people who stopped taking the opioid may be managed by using opioids or non-opioid adjuncts. Methadone is an opioid commonly used for this kind of therapy. However, the selection of therapy should be tailored to each specific person. Methadone also is used for detoxification in people who have opiate addiction, such as heroin or drugs similar to morphine. It may be given orally or intramuscularly. There is controversy regarding whether any opioid (such as methadone) should be included in the treatment of opioid withdrawal symptoms, since these agents also may cause relapse when therapy is suspended. Clonidine is a non-opioid adjunct which may be used in situations where opioid use is not desired, such as in patients with high blood pressure.

Sources: en.wikipedia.org

Reference notes

In 2008, Air Chief Marshal Sir Glenn Torpy Head of the Royal Air Force, for his part in Operation Telic / Operation Iraqi Freedom. Lieutenant General Sir James Dutton, Royal Marines, "in recognition of meritorious, gallant and distinguished services during coalition operations in Afghanistan". Major General Colin Boag, British Army, "in recognition of gallant and distinguished services during coalition operations in Iraq" (March 2008). Lieutenant General James Bucknall, British Army, "in recognition of gallant and distinguished services during coalition operations in Iraq" (July 2009). Major General Mohamed Elkeshky, Egyptian Army Defense, Military, Naval and Air Attaché to the United States. (2013). In 2011, Vice Admiral Tomohisa Takei, Japan Maritime Self-Defense Force, "as recognition for Takei's exceptional leadership and expertise in maturing and expanding the JMSDF and U.S. Navy partnership during his role as director of operations and plans department, JMSDF Maritime Staff Office from April 2008 to July 2010". In 2013, Lieutenant General Walter Souza Braga Netto, Brazilian Army, Military Attaché to the United States of America. "For exceptionally meritous conduct in the performance of outstanding services from March 2011 to May 2013. In 2014, Air Commodore David Best, United Kingdom Royal Air Force. "For exceptionally meritorious service as Director of Air Operations, International Security Assistance Force, from December 2010 to December 2011". In 2014, Major General Brett Cairns, Canadian Air Force, NORAD J3.

=== Generic names === Oxandrolone is the generic name of the drug and its INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name, USPTooltip United States Pharmacopeia, BANTooltip British Approved Name, DCFTooltip Dénomination Commune Française, DCITTooltip Denominazione Comune Italiana, and JANTooltip Japanese Accepted Name, while ossandrolone is or was formerly the DCITTooltip Denominazione Comune Italiana.

=== Food chain supply problems and the IRGC === The food supply chain consists of five main stages: production, handling and storage, processing and packaging, distribution and retail, and finally, consumption. It differs significantly from a regular supply chain due to the perishability of products, strict safety regulations, and the need for precise temperature control, especially in cold chain logistics. Key challenges include managing condition deviations such as temperature or humidity fluctuations, which can cause spoilage; preventing package damage during transportation; and ensuring compliance with food safety standards. High maintenance costs are also a concern, particularly for perishable and cold chain items, as they require specialized equipment and monitoring. Furthermore, the flow of information across the supply chain is critical, as delays or inaccuracies can lead to inefficiencies and disruptions. The food supply chain demands efficient management, integrated data systems, and adherence to global safety regulations to maintain product quality and minimize losses. In addition to water management, the Islamic Revolutionary Guard Corps (IRGC) plays a significant role in Iran's economy. The IRGC has strategically diversified its operations beyond military and defense industries into critical sectors such as agriculture, construction, telecommunications, and energy. This expansion aligns with Iran's "resistance economy" policy to achieve self-reliance and mitigate the impacts of international sanctions.

Sources: en.wikipedia.org

Notes from published material

A qullqa (Quechua pronunciation: [ˈqʊʎˌqa] "deposit, storehouse"; (spelling variants: colca, collca, qolca, qollca) was a storage building found along roads and near the cities and political centers of the Inca Empire. These were large stone buildings with roofs thatched with "ichu" grass, or what is known as Peruvian feathergrass (Jarava ichu). To a "prodigious [extent] unprecedented in the annals of world prehistory" the Incas stored food and other commodities which could be distributed to their armies, officials, conscripted laborers, and, in times of need, to the populace. The uncertainty of agriculture at the high altitudes which comprised most of the Inca Empire was among the factors which probably stimulated the construction of large numbers of qullqas.

=== Diagnosis of HIV infection === Each of the three widely used methods for diagnosing HIV infection has been developed using recombinant DNA. The antibody test (ELISA or western blot) uses a recombinant HIV protein to test for the presence of antibodies that the body has produced in response to an HIV infection. The DNA test looks for the presence of HIV genetic material using reverse transcription polymerase chain reaction (RT-PCR). Development of the RT-PCR test was made possible by the molecular cloning and sequence analysis of HIV genomes. HIV testing page from US Centers for Disease Control (CDC)

Neohormones are a group of recently evolved hormones primarily associated to the success of mammalian development. These hormones are specific to mammals and are not found in other vertebrates—this is because neohormones are evolved to enhance specific mammalian functions. In males, neohormones play important roles in regulating testicular descent (the testes descend into the scrotum during foetal development) and preparing the sperm for internal fertilisation (the sperm fertilizes the egg within the female). In females, neohormones are essential for regulating early pregnancy, mammary gland development lactation (secretion of milk from the mammary gland), and viviparity (allowing the fertilized egg to grow inside the female until they can exist independently). Neohormones superimpose their actions on the hypothalamic-pituitary-gonadal axis (a hormone system which regulates key reproductive functions in animals) and are not associated with other core bodily functions.

Sources: en.wikipedia.org

Frequently asked questions

Is AOD-9604 the same as human growth hormone?

No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.

Was AOD-9604 approved for weight loss?

It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.

Why is AOD-9604 banned in sports?

WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.

Is AOD-9604 approved for medical use?

No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.

Network